180 related articles for article (PubMed ID: 8979133)
1. Plaque rupture, thrombosis, and therapeutic implications.
Fuster V; Badimon J; Chesebro JH; Fallon JT
Haemostasis; 1996 Oct; 26 Suppl 4():269-84. PubMed ID: 8979133
[TBL] [Abstract][Full Text] [Related]
2. Human lesion studies.
Fuster V
Ann N Y Acad Sci; 1997 Apr; 811():207-24; discussion 224-5. PubMed ID: 9186599
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic plaque rupture and thrombosis. Evolving concepts.
Fuster V; Stein B; Ambrose JA; Badimon L; Badimon JJ; Chesebro JH
Circulation; 1990 Sep; 82(3 Suppl):II47-59. PubMed ID: 2203564
[TBL] [Abstract][Full Text] [Related]
4. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.
Corti R; Hutter R; Badimon JJ; Fuster V
J Thromb Thrombolysis; 2004 Feb; 17(1):35-44. PubMed ID: 15277786
[TBL] [Abstract][Full Text] [Related]
5. Atherothrombosis: mechanisms and clinical therapeutic approaches.
Fuster V; Badimon JJ; Chesebro JH
Vasc Med; 1998; 3(3):231-9. PubMed ID: 9892516
[TBL] [Abstract][Full Text] [Related]
6. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model.
Abela GS; Picon PD; Friedl SE; Gebara OC; Miyamoto A; Federman M; Tofler GH; Muller JE
Circulation; 1995 Feb; 91(3):776-84. PubMed ID: 7828306
[TBL] [Abstract][Full Text] [Related]
7. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L
Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872
[TBL] [Abstract][Full Text] [Related]
8. Individualized antithrombotic therapy.
Lüscher TF; Steffel J
Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
[TBL] [Abstract][Full Text] [Related]
9. [Platelets and arterial thrombosis].
Cazenave JP; Gachet C; Lanza F; Wiesel ML
Bull Acad Natl Med; 2003; 187(1):35-44; discussion 45-6. PubMed ID: 14556452
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis and acute coronary events.
Dalager-Pedersen S; Ravn HB; Falk E
Am J Cardiol; 1998 Nov; 82(10B):37T-40T. PubMed ID: 9860372
[TBL] [Abstract][Full Text] [Related]
11. [The pathogenesis of the evolution of the atheroma plaque].
Ferreira Montero IJ; Ferreira Aguar AI; Casasnovas Lenguas JA
Rev Esp Cardiol; 1995; 48 Suppl 5():13-22. PubMed ID: 7494935
[TBL] [Abstract][Full Text] [Related]
12. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Rauch U; Osende JI; Fuster V; Badimon JJ; Fayad Z; Chesebro JH
Ann Intern Med; 2001 Feb; 134(3):224-38. PubMed ID: 11177336
[TBL] [Abstract][Full Text] [Related]
13. The three mechanisms for coronary artery disease progression: insights into future management.
McLaughlin MA; Fuster V
Mt Sinai J Med; 1995 Sep; 62(4):265-74. PubMed ID: 7565849
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor and coronary artery disease.
Moons AH; Levi M; Peters RJ
Cardiovasc Res; 2002 Feb; 53(2):313-25. PubMed ID: 11827681
[TBL] [Abstract][Full Text] [Related]
15. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
16. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
Fuster V
Circulation; 1994 Oct; 90(4):2126-46. PubMed ID: 7718033
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.
Fernández-Ortiz A; Badimon JJ; Falk E; Fuster V; Meyer B; Mailhac A; Weng D; Shah PK; Badimon L
J Am Coll Cardiol; 1994 Jun; 23(7):1562-9. PubMed ID: 8195515
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation and anticoagulation.
Maxim R
Med Health R I; 2001 Mar; 84(3):96-7. PubMed ID: 11280139
[No Abstract] [Full Text] [Related]
19. [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Reikvam A; Madsen S; Landmark K
Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1838-40. PubMed ID: 12830258
[TBL] [Abstract][Full Text] [Related]
20. Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention.
Davies MJ
Eur Heart J; 1995 Nov; 16 Suppl L():3-7. PubMed ID: 8869011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
